Skip to main content
SpringerLink
Log in

Policy medicine versus policy quackery: Economists against the FDA

  • Articles
  • Published:
Knowledge, Technology & Policy

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  • Beales, J. H. III. 1997. “The Health Consequences of Decisions About Drugs.” Ms. George Washington University, Department of Strategic Management and Public Policy.

  • Calfee, John 1996. “The Leverage Principle in the FDA’s Regulation of Information,” in Competitive Strategies in the Pharmaceutical Industry, ed. R. B. Helms, 306–21. Washington, D.C.: American Enterprise Institute.

    Google Scholar 

  • Campbell, Noel 1997. “Replace FDA Regulation of Medical Devices with Third-Party Certification.” Policy Analysis No. 288. Cato Institute, November 12.

  • Grabowski, Henry and John Vernon. 1983. The Regulation of Pharmaceuticals: Balancing the Benefits and Risks. Washington, D.C.: American Enterprise Institute.

    Google Scholar 

  • Higgs, Robert. 1995. “How FDA is Causing a Technological Exodus: A Comparative Analysis of Medical Device Regulation B United States, Europe, Canada, and Japan.” Competitive Enterprise Institute, March, Washington, D.C.

    Google Scholar 

  • Keith, Alison. 1995. “Regulating Information About Aspirin and the Prevention of Heart Attack.” American Economic Review 85, May: 96–99.

    Google Scholar 

  • Pearson, Durk and Sandy Shaw. 1993. Freedom of Informed Choice: FDA Versus Nutrient Supplements. Neptune, NJ: Common Sense Press.

    Google Scholar 

  • Peltzman, Sam. 1973. “The Benefits and Costs of New Drug Regulation.” pp. 114–211 in Regulating New Drugs, ed. Richard L. Landau. Chicago: University of Chicago Press.

    Google Scholar 

  • Rubin, Paul 1995. “FDA Advertising Restrictions: Ignorance Is Death.” In Hazardous to Our Health? FDA Regulation of Health Care Products, edited by Robert Higgs: 29–53. Oakland: The Independent Institute.

    Google Scholar 

  • Statman, Meir. 1983. Competition in the Pharmaceutical Industry: The Declining Profitability of Drug Innovation. Washington, D.C.: American Enterprise Institute.

    Google Scholar 

  • Tabarrok, Alexander. 2000. Assessing the FDA Via The Anomaly of Off-Label Drug Prescribing, The Independent Review 5, #1: pp. XX-XX.

    Google Scholar 

  • Temin, Peter. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge: Harvard University Press.

    Google Scholar 

  • Weidenbaum, Murray. 1993. “Are Drug Prices Too High?” The Public Interest, Summer: 84–89.

Download references

Authors
  1. Daniel Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Daniel Klein received his Ph.D. from NYU where he studied under Israel Kirzner. He taught at U.C. Irvine before joining the Santa Clara University’s faculty in 1996. His teaching and research interests lie in public policy issues (especially road transportation), American economic history, game theory, and the intersection of economics with moral and political philosophy. Professor Klein is the author of Assurance and Trust in a Great Society, FEE, 2000. Dr. Klein is a member of the Editorial Board of KT&P.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klein, D. Policy medicine versus policy quackery: Economists against the FDA. Know Techn Pol 13, 92–101 (2000). https://doi.org/10.1007/s12130-000-1006-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12130-000-1006-x

Keywords

Search

Navigation